"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Descriptor ID |
D001500
|
MeSH Number(s) |
D20.215.894.135.825.100
|
Concept/Terms |
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
|
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 0 | 1 | 1 |
1998 | 1 | 0 | 1 |
2001 | 1 | 1 | 2 |
2002 | 1 | 0 | 1 |
2003 | 2 | 0 | 2 |
2004 | 4 | 2 | 6 |
2005 | 3 | 5 | 8 |
2006 | 2 | 2 | 4 |
2007 | 4 | 3 | 7 |
2008 | 6 | 5 | 11 |
2009 | 5 | 1 | 6 |
2010 | 0 | 4 | 4 |
2011 | 1 | 1 | 2 |
2012 | 4 | 2 | 6 |
2013 | 7 | 3 | 10 |
2014 | 5 | 2 | 7 |
2015 | 8 | 2 | 10 |
2016 | 2 | 6 | 8 |
2017 | 2 | 3 | 5 |
2018 | 7 | 5 | 12 |
2019 | 5 | 0 | 5 |
2020 | 10 | 3 | 13 |
2021 | 13 | 12 | 25 |
2022 | 2 | 8 | 10 |
2023 | 0 | 9 | 9 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Statins and BCG response: Is there more to the story? Scott Med J. 2024 Feb; 69(1):1-2.
-
Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
-
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596. Eur Urol Oncol. 2024 Apr; 7(2):301.
-
Bacillus Calmette-Gu?rin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023 Oct 04; 24(1):636.
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
-
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Gu?rin or Early Radical Cystectomy. Eur Urol Oncol. 2023 12; 6(6):590-596.
-
Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
-
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Gu?rin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 10; 6(5):531-534.
-
Bacillus Calmette-Gu?rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal? BJU Int. 2023 10; 132(4):384-386.
-
The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023 05; 23(5):531-543.